{"id":"semaglutide-j","safety":{"commonSideEffects":[{"rate":"20–40%","effect":"Nausea"},{"rate":"5–15%","effect":"Vomiting"},{"rate":"10–20%","effect":"Diarrhea"},{"rate":"10–20%","effect":"Constipation"},{"rate":"5–15%","effect":"Abdominal pain"},{"rate":"5–10%","effect":"Headache"},{"rate":"5–10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4752331","moleculeType":"Unknown","molecularWeight":"4113.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Semaglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also acts on central and peripheral GLP-1 receptors to reduce appetite, increase feelings of fullness, and slow gastric emptying, leading to reduced caloric intake and improved glycemic control. The drug has demonstrated cardiovascular and weight loss benefits beyond glucose lowering.","oneSentence":"Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, promote satiety, and slow gastric emptying.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:52.307Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Chronic weight management in adults with obesity or overweight"}]},"trialDetails":[{"nctId":"NCT05478252","phase":"PHASE3","title":"A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-08-03","conditions":"Diabetes Mellitus, Type 2","enrollment":388},{"nctId":"NCT05784402","phase":"PHASE1","title":"A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-03-16","conditions":"Healthy Participants","enrollment":264},{"nctId":"NCT06642584","phase":"PHASE1","title":"A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-10-15","conditions":"Healthy Volunteers Type 2 Diabetes","enrollment":90},{"nctId":"NCT06097390","phase":"PHASE1","title":"A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-28","conditions":"Healthy Participants","enrollment":121}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Semaglutide J","genericName":"Semaglutide J","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, promote satiety, and slow gastric emptying. Used for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}